147 related articles for article (PubMed ID: 37442373)
1. Role of bla
Gálvez-Benítez L; de la Rosa JMO; Rodriguez-Villodres A; Casimiro-Soriguer CS; Molina-Panadero I; Alvarez-Marin R; Bonnin RA; Naas T; Pachón J; Cisneros JM; Lepe JA; Smani Y
J Infect; 2023 Sep; 87(3):220-229. PubMed ID: 37442373
[TBL] [Abstract][Full Text] [Related]
2. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
[TBL] [Abstract][Full Text] [Related]
3. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
Rodríguez-Villodres Á; Gil-Marqués ML; Álvarez-Marín R; Bonnin RA; Pachón-Ibáñez ME; Aguilar-Guisado M; Naas T; Aznar J; Pachón J; Lepe JA; Smani Y
J Antimicrob Chemother; 2020 Jan; 75(1):77-85. PubMed ID: 31613964
[TBL] [Abstract][Full Text] [Related]
4. Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
Hansen KH; Andreasen MR; Pedersen MS; Westh H; Jelsbak L; Schønning K
J Antimicrob Chemother; 2019 Nov; 74(11):3179-3183. PubMed ID: 31411684
[TBL] [Abstract][Full Text] [Related]
5. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
[TBL] [Abstract][Full Text] [Related]
6. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla
Hubbard ATM; Mason J; Roberts P; Parry CM; Corless C; van Aartsen J; Howard A; Bulgasim I; Fraser AJ; Adams ER; Roberts AP; Edwards T
Nat Commun; 2020 Oct; 11(1):4915. PubMed ID: 33004811
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
[TBL] [Abstract][Full Text] [Related]
9. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase (ESBL)-producing versus non-ESBL-producing Escherichia coli in a hollow-fibre infection model.
Islam K; Sime FB; Bauer MJ; Forde BM; Wallis SC; Harris P; Naicker S; Shirin T; Habib ZH; Flora MS; Roberts JA
Int J Antimicrob Agents; 2022 Aug; 60(2):106623. PubMed ID: 35728714
[TBL] [Abstract][Full Text] [Related]
13. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
[TBL] [Abstract][Full Text] [Related]
14. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
[TBL] [Abstract][Full Text] [Related]
17. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
[TBL] [Abstract][Full Text] [Related]
19. Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Shahi SK; Singh VK; Kumar A
PLoS One; 2013; 8(7):e68234. PubMed ID: 23861873
[TBL] [Abstract][Full Text] [Related]
20. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
